Physician profile
Carl David Akin
NPI 1871598052
$2,998.46
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $536 · 2021: $773 · 2022: $498 · 2023: $29.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $653.92 | 2019-2022 | |
| Amgen INC. | $577.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $266.32 | 2019-2022 | |
| Amarin Pharma, INC. | $189.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.30 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $173.47 | 2019-2022 | |
| Pfizer INC. | $134.37 | 2019-2022 | |
| Boston Scientific Corporation | $132.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $128.05 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $110.73 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $79.13 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $55.30 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.71 | 2021-2022 | |
| Nuwellis, INC. | $31.72 | 2021 | |
| Biotronik INC. | $31.66 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $30.73 | 2019-2020 | |
| Philips North America LLC | $29.30 | 2023 | |
| Merck Sharp & Dohme LLC | $27.95 | 2021-2022 | |
| Esperion Therapeutics, INC. | $27.53 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.40 | 2020 | |
| Aegerion Pharmaceuticals, INC. | $20.15 | 2019 | |
| Z-Medica, LLC | $20.04 | 2019 | |
| Amryt Pharma Holdings LTD | $16.77 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Akin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.